GMAB News and Press, Genmab A/S From 01/19/24

2024-01-19 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-16 08:22:47 ET Losers: Allakos ALLK -54% announces on restructuring plans . Applied UV ( AUVI ) -18% announces receipt of significant orders in smart building technologies division . Applied Digital Corporation APLD -12% after Q2 earnings rele...

2024-01-11 23:20:33 ET Summary Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown impressive financial performance and secured regul...

2024-01-09 07:13:52 ET More on Genmab, Pfizer, etc. Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Pfizer: 50% Down From The Highs, Generous Dividend, And Robust Balance Sheet Pfizer: Paying Too Much To Boost Revenues Pfizer wins...

– Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy – Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted...

TIVDAK sBLA accepted for priority review, FDA action date is May 9, 2024 Submission based on positive results from global phase 3 innovaTV 301 trial demonstrating overall survival benefit of tisotumab vedotin-tftv over chemotherapy Genmab A/S (Nasdaq: GMAB) and Pfizer, I...

2024-01-08 14:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-23 04:18:53 ET Summary AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product la...

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...